Wiley Acquires Emerald, Expanding Research Scale and Deepening Proprietary Content Across the AI-Driven Knowledge Economy Wiley a global leader in authoritative content and research intelligence, announced it has acquired Emerald Publishing Limited (“Emerald”) from Cambridge Information Group (CIG) in an…
GE HealthCare Focuses on Expanding Access to Nuclear Medicine Through AI, Radiopharmaceutical and Imaging Innovations As theranostics adoption acceleratesi and radiopharmaceutical demand grows,ii healthcare systems are under increasing pressure to scale nuclear medicine operations while improving diagnostic confidence and workflow efficiency. At…
Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement Rallybio Corporation and Avenzo Therapeutics, Inc. a clinical-stage biotechnology company developing next-generation oncology therapies, announced that they have entered into a definitive…
Single Blood Test Simultaneously Captures Immune, Stromal, and Tumor Signals Linked to Immunotherapy Response and Resistance in Sarcoma Aqtual, Inc., a precision medicine company developing active chromatin cell-free DNA (cfDNA) diagnostics for oncology and chronic disease, announced new findings demonstrating…
Qurient Announces First Patient Dosed in Phase 2 Trial of Novel CDK7 Inhibitor Mocaciclib (Q901) for the treatment of HR-Positive Breast Cancer Qurient Co., Ltd. announced that the first patient has been dosed in a Phase 2 clinical study evaluating…
PanTher Completes Dose Escalation Phase in Non-Metastatic Pancreatic Cancer Phase 1b Trial and Appoints Tim Clackson to the Board of Directors PanTher Therapeutics a clinical-stage company redefining early cancer treatment with therapeutic implants administered directly at the tumor site, announced…
FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC) Merck known as MSD outside of the United States and Canada, announced that…
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer AstraZeneca’s IMFINZI® in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the…
Hexcel, NIAR Break Ground on New Hexcel Applications Center at Wichita State University Hexcel Corporation a global leader in advanced composite materials, announced the groundbreaking of the Hexcel Applications Center at Wichita State University’s National Institute for Aviation Research (NIAR).…
Graco Foundation Marks Company’s Centennial with $1 Million Commitment to Minnesota Nonprofits In celebration of Graco’s 100th anniversary, the Graco Foundation announced a $1 million Centennial Impact Initiative to support 10 Minnesota nonprofit organizations advancing self-sufficiency, stability and workforce development,…
ICON Reports Fourth Quarter and Full Year 2025 Results and Provides Outcome of Audit Committee Investigation ICON plc a world-leading clinical research organization, reported its financial results for the fourth quarter and full year 2025, and announced the outcome of its…
Secretome Therapeutics Announces $30 Million Series A Financing From RA Capital Management to Advance STM-01 for Duchenne-Associated Cardiomyopathy Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), announced the closing of a $30…